Get the Stockscreener App
3.16
0.96%
0.03
After Hours:
3.16
Voyager Therapeutics Inc stock is traded at $3.16, with a volume of 338.68K.
It is up +0.96% in the last 24 hours and down -18.77% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$3.13
Open:
$3.11
24h Volume:
338.68K
Relative Volume:
0.93
Market Cap:
$176.11M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
4.8615
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
+5.69%
1M Performance:
-18.77%
6M Performance:
-60.55%
1Y Performance:
-59.17%
1-Day Range:
$3.07
$3.1992
1-Week Range:
$2.925
$3.34
52-Week Range:
$2.75
$9.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.16 | 176.11M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager Therapeutics stock hits 52-week low at $2.81 - Investing.com
Voyager Therapeutics stock hits 52-week low at $2.81 By Investing.com - Investing.com Canada
Institutional investors may adopt severe steps after Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) latest 15% drop adds to a year losses - simplywall.st
7 Analysts Assess Voyager Therapeutics: What You Need To Know - Benzinga
Voyager Therapeutics chief medical officer sells $34,594 in stock By Investing.com - Investing.com India
Top Executives Unload Thousands of Voyager Therapeutics Shares! - TipRanks
Voyager Therapeutics chief medical officer sells $34,594 in stock - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.54 By Investing.com - Investing.com Philippines
Voyager reveals promising Alzheimer’s therapy data By Investing.com - Investing.com South Africa
Voyager Therapeutics stock hits 52-week low at $3.54 - Investing.com
Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025 - Nasdaq
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - The Manila Times
Voyager reveals promising Alzheimer’s therapy data - Investing.com
New Alzheimer's Breakthrough: Single-Dose Gene Therapy Slashes Tau Levels by 73% - Stock Titan
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, - GlobeNewswire
Voyager Therapeutics at Virtual CNS Forum: Strategic Insights on Neurotherapeutics - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Canaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00 - Armenian Reporter
Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright - Defense World
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN
Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates - MSN
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock By Investing.com - Investing.com Canada
Voyager Therapeutics’ Earnings Call Highlights Promising Future - TipRanks
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts - Benzinga
Voyager Therapeutics stock hits 52-week low at $3.67 - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.67 By Investing.com - Investing.com Australia
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo - TipRanks
Voyager Therapeutics Inc earnings missed by $0.22, revenue fell short of estimates - Investing.com
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings - Investing.com Australia
Voyager Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings By Investing.com - Investing.com South Africa
Voyager Therapeutics: Q4 Earnings Snapshot - mySA
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VOYAGER THERAPEUTICS Earnings Results: $VYGR Reports Quarterly Earnings - Nasdaq
Voyager Therapeutics, Inc. SEC 10-K Report - TradingView
Voyager Therapeutics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - TradingView
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire Inc.
VOYAGER THERAPEUTICS Earnings Preview: Recent $VYGR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Increases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Voyager Therapeutics Inc Stock (VYGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Apr 02 '25 |
Sale |
3.43 |
10,885 |
37,336 |
430,931 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):